CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Leal Therapeutics raises $30m to fund schizophrenia and ALS trials

Positive
AI Analysis

Summary

Leal Therapeutics completed a $30 million Series A extension to fund advancement of its investigational therapies for schizophrenia and ALS through clinical trials.

Importance:5/10
Sentiment:
0.60
financingSeries A extensionschizophreniaALSclinical trials
Related Companies

Read the original article

Published by Clinical Trials Arena on August 18, 2026 8:01 AM

Read Original